Table 1.
Patient characteristics by race and ethnicity.
| Patient characteristic | NH-White n % | NH-Black n % | Hispanic n % | Asian/Pacific Islander n % | Other n % | Total | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Treatment | CTP- > Placebo | 526 (33.6) | 25 (31.3) | 21 (28.4) | 46 (36.5) | 7 (25.9) | 625 |
| CTB- > Placebo | 519 (33.1) | 28 (35.0) | 28 (37.5) | 39 (31.0) | 11 (40.7) | 625 | |
| CTB- > Bevacimmab | 521 (33.3) | 27 (33.8) | 25 (33.5) | 41 (32.5) | 9 (33.3) | 623 | |
| Age Cioup | <60 years | 752 (48.0) | 38 (475) | 51 (68.9) | 80 (63.5) | 14 (51.9) | 935 |
| 60–69 years | 518 (33.1) | 32 (40.0) | 14 (18.5) | 38 (30.2) | 8 (29.6) | 610 | |
| ≥70 years | 296 (18.9) | 10 (12.5) | 9 (12.2) | 8 (6.3) | 5 (18.5) | 328 | |
| Performance Status | 0 | 761 (48.6) | 41 (51.3) | 37 (50.0) | 81 (64.3) | 11 (40.7) | 931 |
| 1 | 697 (44.5) | 31 (38.8) | 32 (43.2) | 38 (30.2) | 11 (40.7) | 809 | |
| 2 | 108 (6.9) | 8 (10.0) | 5 (6.5) | 7 (5.6) | 5 (18.5) | 133 | |
| Primary Site | Ovary | 1300 (83.0) | 73 (91.3) | 63 (85.1) | 109 (86.5) | 18 (66.7) | 1563 |
| Fallopian tube | 30 (1.9) | 0 (0.0) | 3 (4.1) | 2 (1.6) | 1 (3.7) | 36 | |
| Primary peritoneum | 236 (15.1) | 7 (8.8) | 8 (10.8) | 15 (11.9) | 8 (29.6) | 274 | |
| Histology | Papillaiy serous | 1342 (85.7) | 67 (83.8) | 58 (78.4) | 96 (76.2) | 22 (81.5) | 1585 |
| Endometrioid | 4S (3.1) | 4 (5.0) | 1 (1.4) | 6 (4.8) | 0 (0.0) | 59 | |
| Clear cell | 40 (2.6) | 1 (1.3) | 4 (5.4) | 7 (5.6) | 3 (11.1) | 55 | |
| Mucinous | 15 (1.0) | 1 (1.3) | 1 (1.4) | 1 (0.8) | l (3.7) | 19 | |
| Adenocarcinoma, not specified | 20 (1.3) | 0 (0.0) | 0 (0.0) | 4 (3.2) | 0 (0.0) | 24 | |
| Transitional cell | 10 (0.6) | 2 (2.5) | 0 (0.0) | 4 (3.2) | 0 (0.0) | 16 | |
| Mixed adenocarcinoma | 64 (4.1) | 5 (6.3) | 9 (12.2) | 6 (4.8) | 1 (3.7) | 85 | |
| Undifferentiated carcinoma | 20 (1.3) | 0 (0.0) | 1 (1.4) | 0 (0.0) | 0 (0.0) | 21 | |
| Other | 7 (0.4) | 0 (0.0) | 0 (0.0) | 2 (1.6) | 0 (0.0) | 9 | |
| Stage, Residual size | III-optimal | 537 (34.3) | 22 (27.5) | 25 (33.5) | 46 (36.5) | 10 (37.0) | 640 |
| III-subofstimal | 629 (40.2) | 38 (47.5) | 24 (32.4) | 51 (40.5) | 10 (37.0) | 752 | |
| IV | 400 (25.5) | 20 (25.0) | 25 (33.5) | 29 (23.0) | 7 (25.9) | 481 | |
| BMI | <25 | 703 (44.9) | 22 (27.5) | 34 (459) | 100 (79.4) | 8 (29.6) | 867 |
| 25–29.9 | 424 (27.1) | 18 (225) | 22 (29.7) | 21 (16.7) | 7 (25.9) | 492 | |
| 230 | 439 (28.0) | 40 (50.0) | 18 (24.3) | 5 (4.0) | 12 (44.4) | 514 | |
| Total | 1566 | 80 | 74 | 126 | 27 | 1873 | |
The treatment regimens were carboplatin, paclitaxel and placebo for cycles 1–6 followed by placebo for cycles 7–22 (CTP->Placebo); carboplatin, paclitaxel for cycles 1–6 and bevacizumab for cycles 2–6 followed by placebo for cycles 7–22 (CTB->Placebo); carboplatin, paclitaxel for cycles 1–6 and bevacizumab for cycles 2–6 followed by bevacizumab for cycles 7–22 (CTB->Bevacizumab). Twenty-seven patients were listed in the other category and this group comprised seven American Indian/Alaskan native patients and twenty patients who did not specify a racial or ethnic group. NH=Non-Hispanic.